Key facts
- This page summarizes Daniel Dolan's Form 4 filing for Nabriva Therapeutics plc.
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 01 Feb 2022, 17:39.
Daniel Dolan - 28 Jan 2022 Form 4 Insider Report for Nabriva Therapeutics plc
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- N/A
- Reported as of
- 28 Jan 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Feb 2022, 17:39:01 UTC
- Next SEC filing
- 15 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ J. Christopher Naftzger, by power of attorney
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Daniel Dolan filed Form 4 for Nabriva Therapeutics plc on 01 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NBRV
transaction
Derivative
Share Options
Award
- Transaction value
- $0
- Shares
- +83,200
- Change %
- Price
- $0.000000
- Shares after
- 83,200
- Date
- 28 Jan 2022
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 83,200
- Exercise price
- $0.4500
- Footnotes
- F1, F2
NBRV
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +41,600
- Change %
- Price
- $0.000000
- Shares after
- 41,600
- Date
- 28 Jan 2022
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 41,600
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval is not obtained, the option will remain outstanding and convert into a cash-settled share appreciation right.
Footnote F2
Subject to the reporting person's continued employment with Nabriva Therapeutics plc (the "Issuer"), the option will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the option will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the option will vest on a monthly pro-rata basis over the remaining vesting period.
Footnote F3
The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represents a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval is not obtained, then each RSU will represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date.
Footnote F4
Subject to the reporting person's continued employment with the Issuer, the RSUs will vest in equal annual installments over four years with the first installment vesting on January 28, 2023.